Premium
Paediatric Burkitt lymphoma patient‐derived xenografts capture disease characteristics over time and are a model for therapy
Author(s) -
Forde Sorcha,
Matthews Jamie D.,
Jahangiri Leila,
Lee Liam C.,
Prokoph Nina,
Malcolm Tim I.M.,
Giger Olivier T.,
Bell Natalie,
Blair Helen,
O'Marcaigh Aengus,
Smith Owen,
Kenner Lukas,
Bomken Simon,
Burke Gladstone A. A.,
Turner Suzanne D.
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17043
Subject(s) - medicine , lymphoma , salvage therapy , oncology , disease , refractory (planetary science) , rituximab , clinical trial , chemotherapy , immunology , cancer research , biology , astrobiology
Summary Burkitt lymphoma (BL) accounts for almost two‐thirds of all B‐cell non‐Hodgkin lymphoma (B‐NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient‐derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.